Menopause is not a single event. It is a transition that often begins years before your last period and continues to shape how you sleep, think, and feel long after it. At Atlanta Medical Institute, we treat that whole arc — perimenopause, menopause, and the years beyond — with a plan built around your symptoms, your medical history, and your own priorities.
Most women reach menopause somewhere in their late forties to mid-fifties, and the perimenopausal years leading up to it are when symptoms are often the most unpredictable. Estrogen does not simply decline in a straight line; it fluctuates. That is why a woman can have hot flashes, disrupted sleep, and heavy or erratic periods all in the same season of life, and why a single blood test on a single day rarely tells the whole story.
There is a great deal of good news in menopause care right now, and some genuine nuance. In November 2025, the FDA announced it was initiating removal of the long-standing boxed warnings about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy labeling, and adding guidance about starting systemic therapy within about ten years of menopause onset or before age 60. The boxed warning about endometrial cancer remains for systemic estrogen-alone products. At the same time, new non-hormonal medications have been approved for hot flashes, giving women who cannot or prefer not to take hormones real options for the first time in years.
What has not changed is that this is an individual decision. Nothing on this page is a prescription or a promise of a particular result. Whether hormone therapy or any other treatment is appropriate for you — and at what dose and in what form — is determined by one of our physicians after a full evaluation, and revisited as your health changes.
Program Benefits
- A physician-led evaluation that looks at your symptoms, medical and family history, and current medications before any treatment is proposed
- Discussion of both FDA-approved hormonal and non-hormonal options, including the newer neurokinin-targeted medications for hot flashes
- Attention to symptoms that often go unaddressed — sleep disruption, mood changes, brain fog, joint aches, vaginal dryness, and painful intercourse
- Coordination with your long-term health picture, including bone density, cardiovascular risk factors, and weight changes
- Scheduled follow-up so that dose, formulation, and the decision to continue are reassessed over time rather than set once and forgotten
- One Buckhead office where you see the same physicians visit after visit, rather than a rotating roster
Symptoms We Treat — and the Ones People Do Not Expect
Hot flashes and night sweats are the symptoms most women come in for, and they are among the most treatable. But the menopause transition reaches further than temperature regulation. Many patients tell us the sleep loss and the mood and concentration changes affect their daily lives more than the flashes do.
Genitourinary symptoms deserve particular mention because they are common, they tend to be progressive rather than self-limiting, and they are the ones patients most often hesitate to raise. Vaginal dryness, irritation, painful intercourse, and recurrent urinary symptoms fall under what clinicians now call genitourinary syndrome of menopause. The 2025 joint guideline from the American Urological Association, SUFU, and AUGS recommends offering low-dose vaginal estrogen to patients with these symptoms. Please bring them up. We ask about them directly so that you do not have to.
- Hot flashes and night sweats (vasomotor symptoms)
- Insomnia and fragmented sleep
- Mood changes, irritability, anxiety, low mood
- Difficulty concentrating and word-finding, often described as brain fog
- Vaginal dryness, irritation, and painful intercourse
- Recurrent urinary urgency or urinary tract infections
- Changes in libido
- Joint and muscle aches
- Changes in body composition and weight distribution
- Concerns about bone density and fracture risk
How We Evaluate You
Your first visit is a conversation before it is anything else. One of our physicians takes a full history: the pattern and timing of your symptoms, your menstrual history, prior surgeries, personal and family history of breast cancer, blood clots, stroke, heart disease, liver disease, and osteoporosis, along with everything you currently take, including supplements.
For most women over 45 with typical symptoms, menopause and perimenopause are diagnosed clinically. Guidelines including NICE advise against relying on a follicle-stimulating hormone test to make that diagnosis in this age group, because FSH swings widely during perimenopause and a normal result on a given day does not rule anything out. Laboratory testing still has a role — it can matter when symptoms begin before age 45, when the picture is atypical, or when we need to evaluate thyroid function, metabolic health, or other conditions that mimic menopause. We order the tests that will change the plan, and explain why.
We also review whether you are up to date on age-appropriate screening, including mammography and bone density testing where indicated, and coordinate with your primary care physician or gynecologist when that makes sense.
Treatment Options We Discuss
Systemic hormone therapy remains the most effective treatment for moderate to severe hot flashes and night sweats, and it is also FDA-approved for prevention of postmenopausal osteoporosis. Estrogen is available in several FDA-approved forms, including patches, gels, sprays, and oral tablets; women with a uterus also need a progestogen to protect the endometrium. Many FDA-approved products already contain hormones structurally identical to those the body makes, which is what the word bioidentical actually means.
That distinction matters. Custom-compounded hormone preparations, including pellets and troches, are not FDA-approved and are not tested for consistency of dose or absorption. ACOG's clinical consensus on compounded bioidentical menopausal hormone therapy and the Endocrine Society both advise using FDA-approved products when an appropriate one exists. We will tell you plainly which category any recommended therapy falls into.
For genitourinary symptoms, low-dose vaginal estrogen delivers hormone locally with minimal systemic absorption and can be used by many women who are not candidates for systemic therapy. Vaginal DHEA and ospemifene are additional FDA-approved options. The 2025 AUA/SUFU/AUGS guideline also states that endometrial surveillance is not required solely because a patient is using low-dose vaginal estrogen, vaginal DHEA, or ospemifene.
Non-hormonal medication has advanced meaningfully. Fezolinetant (Veozah), a neurokinin-3 receptor antagonist, was approved in May 2023 for moderate to severe vasomotor symptoms; in December 2024 the FDA added a boxed warning for rare but serious liver injury, along with a schedule of liver blood testing before and during treatment. Elinzanetant (Lynkuet), which blocks both NK1 and NK3 receptors, was approved on October 24, 2025 for the same indication; in the phase 3 OASIS program, women taking it reported substantially fewer moderate to severe hot flashes than those taking placebo. Certain antidepressants and other non-hormonal prescriptions also have evidence behind them for hot flashes. Which of these is suitable — if any — depends on your history, and dosing is set by your physician, not by a chart.
Safety, Monitoring, and Honest Limits
The 2025 labeling changes reflect a better understanding of timing: the risk-benefit picture for systemic hormone therapy is generally more favorable for women who begin within roughly ten years of menopause onset or before age 60, and less favorable when therapy is started much later. Risk is not zero, and it is not the same for everyone. Information about cardiovascular disease and breast cancer remains in the labeling outside the boxed warning, and the endometrial cancer boxed warning stays on systemic estrogen-alone products. A personal history of breast cancer, estrogen-dependent cancer, unexplained vaginal bleeding, active liver disease, or a history of blood clots or stroke changes the conversation considerably, and in some cases rules systemic hormone therapy out.
Results published from clinical trials are averages across a study population. They describe what happened to a group, not what will happen to you. We do not promise symptom elimination, a particular timeline, or a particular number on a lab report.
Monitoring is part of the treatment, not an afterthought. Depending on what you are taking, that may mean a follow-up visit within the first several weeks to assess response and side effects, periodic laboratory testing, liver function testing on the FDA-recommended schedule if you are prescribed fezolinetant, and an ongoing discussion about whether to continue, adjust, or stop. Report new or unusual vaginal bleeding, chest pain, shortness of breath, leg swelling, severe headache, yellowing of the skin or eyes, or dark urine to us promptly.
What to Expect at Our Buckhead Office
Atlanta Medical Institute has been caring for patients from a single office at 5009 Roswell Road NE, Suite 201, in Buckhead since 2010. Your menopause care is directed by our physicians — Dr. Elbridge Bills, M.D., who focuses on bioidentical hormone therapy, and Dr. Leslye Pace, M.D., our Chief Medical Officer — with anti-aging and wellness support from Dr. Jeff Semel, D.C., ABAAHP. You can read more about each of them at /about/dr-elbridge-bills, /about/dr-jeff-semel, and /about/dr-leslye-pace.
Plan on a longer first appointment. We would rather spend the time up front than hand you a protocol. After the initial evaluation and any testing, we review the findings with you, lay out the options that genuinely apply to your situation, and start with the least burdensome approach that is likely to help. Office hours are Monday through Thursday, 9 to 6, and Friday, 9 to 4. To schedule, call (404) 264-9553 or use the form at /contact.
How This Fits With Our Other Services
Menopause care rarely stands alone. If your primary concern is hot flashes and night sweats, our dedicated page at /services/hot-flashes-treatment goes into the treatment options in more depth. If you are considering hormone therapy specifically, see /services/hormone-replacement-therapy and /services/bioidentical-hormone-replacement-therapy.
Weight change during the menopause transition is a frequent reason patients come to us, and it is a separate clinical evaluation with its own considerations; you can read about our medically supervised approach at /services/weight-loss-atlanta-ga. Joint pain that worsens in these years may warrant its own workup — see /services/arthritis-treatment. Broader healthy-aging care is described at /services/anti-aging-treatments. Patient experiences are at /reviews, and our practice background is at /about.
Frequently Asked Questions
Is hormone therapy safe?+
Safety depends on the individual, the formulation, and when therapy is started. In November 2025 the FDA announced it was initiating removal of the boxed warnings about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy labeling, and adding guidance about starting systemic therapy within about ten years of menopause onset or before age 60. The endometrial cancer boxed warning remains for systemic estrogen-alone products, and information about cardiovascular disease and breast cancer remains in the labeling outside the boxed warning. Risk is not zero. A physician here will review your personal and family history — including any history of breast or estrogen-dependent cancer, blood clots, stroke, liver disease, or unexplained vaginal bleeding — before recommending anything.
Do I need a blood test to know whether I am in menopause?+
Usually not, if you are over 45 and having typical symptoms. Guidelines including NICE advise against using an FSH test to diagnose menopause in that age group, because FSH fluctuates widely in perimenopause and a single value can be misleading. Testing is more useful when symptoms start before 45, when the presentation is unusual, or when we need to check for thyroid, metabolic, or other conditions that can look like menopause.
Are compounded or pellet hormones better than what a regular pharmacy dispenses?+
No. Compounded preparations, including pellets and troches, are not FDA-approved and are not tested for dose consistency or absorption. ACOG's clinical consensus on compounded bioidentical menopausal hormone therapy and the Endocrine Society both recommend FDA-approved products when a suitable one exists. Many FDA-approved estrogen and micronized progesterone products are already chemically identical to the body's own hormones, so choosing an approved product does not mean giving up bioidentical hormones.
What if I cannot take hormones?+
There are FDA-approved non-hormonal prescription options for moderate to severe hot flashes. Fezolinetant (Veozah) was approved in 2023; it carries a boxed warning for rare but serious liver injury and requires liver blood testing on an FDA-recommended schedule. Elinzanetant (Lynkuet) was approved in October 2025. Some non-hormonal medications used for other conditions also have evidence for hot flashes. For vaginal dryness and painful intercourse, low-dose vaginal estrogen, vaginal DHEA, and ospemifene are options, and non-hormonal moisturizers and lubricants help some patients. Your physician will discuss which of these fits your history.
How long does treatment last?+
There is no fixed endpoint that applies to everyone. The FDA's 2025 labeling update moved away from the old blanket instruction to use the lowest dose for the shortest possible time, in favor of individualized decisions. We reassess at follow-up visits — how you are doing, whether the benefit still outweighs the risk for you, and whether to continue, adjust, or taper. That is a decision you and your physician make together, repeatedly, not once.
Will treatment help with weight gain during menopause?+
Hormone therapy is not a weight-loss treatment, and we do not present it as one. Changes in body composition during this period involve hormones, muscle mass, sleep, activity, and age together. If weight is a primary concern, it warrants its own evaluation; our medically supervised approach is described at /services/weight-loss-atlanta-ga.
Do you handle perimenopause, or only menopause?+
Both. Perimenopause is often when symptoms are most disruptive and least recognized, sometimes years before periods stop. If you are in your forties with irregular cycles, new sleep problems, mood changes, or hot flashes, that is a reasonable time to be evaluated.
How do I get started?+
Call (404) 264-9553 or use the contact form at /contact to schedule an evaluation at our Buckhead office at 5009 Roswell Road NE, Suite 201. We see patients Monday through Thursday from 9 to 6 and Friday from 9 to 4. Bring a list of your current medications and supplements, and any recent lab work or imaging if you have it.
Costs and appointment planning
Review pricing questions, insurance and coverage information, and telehealth visit planning before booking. Confirm the costs and services that apply to your individual care.
Ready to Get Started?
Call us at (404) 264-9553 or book a telehealth consultation. New patients qualify for our 1st month Semaglutide special — $399 (regularly $450).